COVID 19 RESEARCH STUDY
Our group has been an integral Clinical Research Site for the AIDS Clinical Trials Group (ACTG) for HIV research since 1991 in close partnership with the University of North Carolina at Chapel Hill’s clinical trials unit. Our staff and our patients have been an active part of the historical revolution in HIV care that the ACTG has forged in the past several decades. We have also been involved in HIV Prevention studies through the NIH as well as Pharma studies with HIV treatment medications.
With the emergence of the global threat of SARs-Cov 2 and the virus, Covid 19, our efforts are currently being directed to the treatment of patients with the virus and in vaccine development through the ACTG and NIH. We hope that our involvement in this research, will benefit humanity as we seek to learn what we can about Covid 19. Our current ongoing studies will continue but we will not be opening any new studies in HIV and Hep C at this time.
Our new study, A5395 will study the effectiveness of hydroxychloroquine and azithromycin in newly diagnosed individuals with Covid 19. If you are interested in learning more about this study and to see if you would qualify, please contact us at 336-579- 6911 or send an email to email@example.com.
In order to qualify you must
Be 18 years of age or older
Have a positive test of the nose or throat for COVID-19 within 96 hours of starting the study
Be experiencing at least one symptom: fever, cough or shortness of breath
Willing to participate in study visits
Have no medical conditions that make it unsafe for you to participate
Qualifying participants will have a 50/50 chance of receiving either Hydroxychloroquine and Azithromycin or placebos. Participants will have up to two in person or remote study visits and up to 7 telephone visits.